高危型人乳头瘤病毒核酸体外检测试剂盒临床功能验证的中美指导原则解读

为促进人乳头瘤病毒(HPV)检测试剂盒临床功能验证设计的规范化,中国国家食品药品监督管理总局(CFDA)和美国国家食品药品监督管理总局(FDA)分别针对HPV检测试剂盒核酸检测的准确性验证和临床功能,包括不明意义非典型鳞状细胞(ASC-US)人群分流、联合筛查和初筛的有效性验证方面,从临床试验设计或评价等方面推荐了较为详细的指导原则。中美两国指导原则在研究设计、研究对象、样本量估计和统计分析等关键点的要求略有差异,但评价指标类似。按照CFDA指导原则要求,可采用横断面研究设计代替FDA建议的前瞻性设计进行ASC-US人群分流用途的验证;同时采用前瞻性研究设计,对同一个自然人群进行拟申报产品HP...

Full description

Saved in:
Bibliographic Details
Published in中华肿瘤杂志 Vol. 39; no. 7; pp. 553 - 557
Main Author 冯瑞梅 陈汶 乔友林
Format Journal Article
LanguageChinese
Published 100021,国家癌症中心 中国医学科学院北京协和医学院肿瘤医院肿瘤流行病室 2017
Subjects
Online AccessGet full text
ISSN0253-3766
DOI10.3760/cma.j.issn.0253-3766.2017.07.016

Cover

More Information
Summary:为促进人乳头瘤病毒(HPV)检测试剂盒临床功能验证设计的规范化,中国国家食品药品监督管理总局(CFDA)和美国国家食品药品监督管理总局(FDA)分别针对HPV检测试剂盒核酸检测的准确性验证和临床功能,包括不明意义非典型鳞状细胞(ASC-US)人群分流、联合筛查和初筛的有效性验证方面,从临床试验设计或评价等方面推荐了较为详细的指导原则。中美两国指导原则在研究设计、研究对象、样本量估计和统计分析等关键点的要求略有差异,但评价指标类似。按照CFDA指导原则要求,可采用横断面研究设计代替FDA建议的前瞻性设计进行ASC-US人群分流用途的验证;同时采用前瞻性研究设计,对同一个自然人群进行拟申报产品HPV和细胞学平行检测,通过至少3年细胞学随访,对初筛和联合筛查进行拟申报产品的临床有效性验证。
Bibliography:Human papillomavirus ; Guidline ; Evaluation of nucleic acid detection ;Clinical performance evaluation
Feng Ruimei, Chen Wen, Qiao Youlin (Department of Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China)
11-2152/R
To establish the standardization of clinical verification designs for in vitro diagnostic devices(IVDs) of human papillomavirus, China Food and Drug Administration (CFDA) and United States Food and Drug Administration (FDA) issued guidelines of detailed study designs and effectiveness evaluation for accuracy validation and clinical performance of nucleic acid detection, respectively, including triage of a typical squamous cells of undetermined significance(ASC-US) patients and validation of combined screening and preliminary screening. The design, study population, sample size estimation and statistical analysis of guidelines were moderately different from America to China, however, the evaluation indication
ISSN:0253-3766
DOI:10.3760/cma.j.issn.0253-3766.2017.07.016